Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden lupus: study reveals why atypical cases are often missed

NCT ID NCT07350772

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 400 people with lupus to compare those with typical symptoms versus those with unusual or 'atypical' symptoms. The goal is to understand how these differences affect disease activity, organ damage, and treatment needs over time. By identifying these patterns, doctors hope to diagnose and treat atypical lupus earlier and more effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include 400 patients diagnosed according to SLICC classification criteria as systemic lupus erythematosus\[13\] including 3oo patients with typical common SLE presentation and 100 patients with atypical presentation as rare manifestations,ANA negative lupus, late onset lupus.Patients will be collected from Rheumatology outpatient clinic - Sohag University Hospital.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients diagnosed as SLE according toSLICC 2012Classification Criteria\[13\] : A. Patients presented with typical lupus presentation: 1. age of onset (20-50) 2. common initial manifestations as constitutional manifestations,arthritis, mucocutaneousmanifestationslike malar rash, photosensitivity and hair falling. 3. patients with ANA positive. B. Patients presented with atypical lupus presentation: 1. any clinical presentation not belonging to classic common SLE onset features, including but not limited to: * Neuropsychiatric onset: seizure, psychosis, aseptic meningitis, transverse myelitis * Cardiopulmonary onset: pulmonary hypertension, acute pneumonitis, myocarditis, pulmonary hemorrhage * Gastrointestinal onset: mesenteric vasculitis, intestinal pseudo obstruction, pancreatitis * Hematologic severe onset: isolated severe thrombocytopenia, autoimmune hemolytic anemia, thrombotic microangiopathy * Dermatologic atypical onset: bullous lupus, panniculitis, vasculitic ulcers * Myositis * Fever of unknown origin (FUO) as sole initial presentation * Thrombotic events * Generalized lymphadenopathy. 2. Patients with dominant organ affection. 3. patients with late onset SLE. 4. patients with ANA negative SLE. C.Patients who can provide informed consent. exclusion criteria: 1. Patients whose initial symptoms are clearly attributable to infection, sepsis or another non-SLE condition. 2. Patients with chronic pre-existing diseases that may mimic or obscure the initial SLE presentation (e.g. primary epilepsy, primary pulmonary hypertension, chronic liver or GI disease). 3. Patients in whom onset features cannot be reliably classified as typical or atypical due to mixed or unclear presentation. Exclusion Criteria: \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Systemic lupus erythematosus (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Systemic lupus erythematosus (SLE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sohag university hospitals,sohag ,sohag

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.